Eric Van Cutsem, MD, PhD

University Hospital Gasthuisberg/Leuven
Leuven, Belgium

Eric Van Cutsem, MD, PhD, is professor and Division Head of Digestive Oncology at University of Leuven (KUL) and University Hospitals Gasthuisberg, Leuven, Belgium.
He is a member of the Belgian Royal Academy of Medicine and president of the Belgian Foundation against Cancer.
In 2018 he became doctor honoris causa of the Medical University of Warsaw, Poland. He received several awards, amongst which were in 2019 the ESMO Award and the European Awards in Medicine for Cancer Research.
His research focuses on the development of new treatment strategies for various Gastrointestinal cancers. He published >645 articles in PubMed, leading to >90.000 citations and an H-factor of 136.
He co-founded and is chair ESMO-GI/World Congress on Gastrointestinal Cancer, Barcelona. He serves/served on the board or key committee of ESMO (executive board, several committees), ASCO (program committee, international affairs committee), ENET (advisory board), EORTC (executive board, chair of GI Cancer group), ECO, ESDO (European Society Digestive Oncology; president), ESO (European School of Oncology: Scientific council) and of patient advocacy groups EuropaColon (medical director) and Digestive Cancers Europe (DICE; co-founder, executive board).
He was chairman of the governmental colon cancer prevention task force in Flanders, Belgium, was/is presiden/treasurer of Belgian Group Digestive Oncology and as president/vice-president of Familial Polyposis Association (FAPA).
He is/was member of the Scientific Advisory board for different international hospitals/cancer centers: INCA, Toulouse & Paris; University of Ulm & Leipzig Humanitas Hospital, Milan & Avignon, and is member of the board of directors of the regional hospital of Halle, Belgium.

Presentation(s):

• Welcome and Introduction

  Wednesday, June 29, 2022
  13:00 – 13:05

• Session I: Opening Session

  Wednesday, June 29, 2022
  13:00 – 13:30

• Session II: Cancer of the Pancreas

  Wednesday, June 29, 2022
  13:30 – 16:15

• Debate: Molecular Changes in Pancreatic Ductal Adenocarcinoma: NGS in All Patients With PDAC - DISCUSSION

  Wednesday, June 29, 2022
  14:38 – 14:50

• Cases With Panel Discussion: Resectable, Borderline Resectable, and Unresectable Pancreatic Cancer

  Wednesday, June 29, 2022
  14:58 – 15:35

• Treatment of Metastatic Colorectal Cancer

  Wednesday, June 29, 2022
  19:50 – 20:05

• Personalized GI Oncology in Europe - State of the Art and Future Perspectives

  Wednesday, June 29, 2022
  19:00 – 21:00

• Welcome and Introduction

  Wednesday, June 29, 2022
  19:00 – 19:05

• Belgium Report

  Wednesday, June 29, 2022
  19:10 – 19:15

• Panel Discussion

  Wednesday, June 29, 2022
  19:50 – 20:50

• Summary

  Wednesday, June 29, 2022
  20:50 – 21:00

• Session VIII: Esophageal and Gastric Cancers

  Thursday, June 30, 2022
  10:00 – 12:50

• Debate: GE Junction Tumors: Neoadjuvant Chemoradiotherapy (CRT) or Perioperative Chemotherapy (CT) - DISCUSSION

  Thursday, June 30, 2022
  10:54 – 11:04

• Cholangiocarcinoma: It's Time for Personalised Medicine

  Thursday, June 30, 2022
  13:05 – 14:35

• Welcome and Introductions

  Thursday, June 30, 2022
  13:05 – 13:10

• Personalised Medicine in Advanced Cholangiocarcinoma

  Thursday, June 30, 2022
  13:40 – 13:55

• Panel Discuss and Q&A

  Thursday, June 30, 2022
  14:10 – 14:30

• Closing Remarks

  Thursday, June 30, 2022
  14:30 – 14:35

• WCGIC Colloquium 1: Artificial Intelligence in GI Oncology

  Thursday, June 30, 2022
  18:50 – 19:50

• Session X: Presentation of Selected Colorectal Cancer Abstracts

  Friday, July 1, 2022
  08:00 – 09:25

• Session XIV: Keynote Lectures

  Friday, July 1, 2022
  09:30 – 10:20

• Session XXII: Colorectal Cancer: Metastatic Disease

  Saturday, July 2, 2022
  09:30 – 13:15

• Session XXIII: Rare GI Tumors – NETs, GISTs, and Anal Cancer

  Saturday, July 2, 2022
  15:15 – 16:30

• Concluding Remarks

  Saturday, July 2, 2022
  16:25 – 16:30